Phase III Study of sacituzumab govitecan (IMMU-132) Versus Treatment of Physicians Choice (TPC) in Hormonal Receptor Positive (HR+) HER2 Negative Metastatic Breast Cancer (MBC) who have failed at least one prior line of chemotherapy (IMMU-132-09)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Documented evidence of hor one receptor-positive HER2-negative (HR+/HER2-) MBC confirmed 2) Availability of archival tumor tissue FFPE) block (within 12 months prior to rando ization) or newly acquired biopsy (FFPE block) from a metastatic site. 3) Refractory o or relapsed after at least 2, and no ore than 4, prior systemic chemotherapy regimens for MBC including; •At least 1 prior anticancer hormonal treatment. •At least 1 cyclin-dependent kinase inhibitor 4/6 in the metastatic setting.

You may not be eligible for this study if the following are true:

  • 1) Previous treatment with Topoisomerase 1 Inhibitors as a free for or as other formulations 2) History of significant cardiovascular disease or clinically significant EGG abnormality 3) Patients with Gilbert's disease.


If you are registered as a volunteer, please login to the dashboard to send referrals.